Compass Therapeutics
Compass makes antibodies that hit two targets at once to reshape the blood supply and immune environment of tumours. Its lead drug, tovecimig, blocks two blood-vessel growth signals and is heading for a possible US approval filing in bile duct cancer.
Overview
Compass Therapeutics is a Boston clinical-stage, oncology-focused company developing antibody-based therapeutics. Lead candidate tovecimig is a DLL4 x VEGF-A bispecific antibody; data from the COMPANION-002 phase 2/3 study in biliary tract cancer were selected for an oral presentation at ESMO 2026, and the company expects FDA feedback in the third quarter of 2026 ahead of a potential BLA filing later in the year. CTX-8371, a PD-1 x PD-L1 bispecific, is in phase 1 cohort expansions in triple-negative breast cancer, Hodgkin lymphoma and non-small cell lung cancer, and CTX-10726, a PD-1 x VEGF-A bispecific, has dosed its first phase 1 patients with initial data expected in the fourth quarter of 2026. A phase 2 study of CTX-471, a CD137 agonist antibody, in NCAM (CD56)-expressing tumours is planned. Compass had $180 million in cash and marketable securities at 30 June 2026, expected to fund operations into 2028. Nasdaq: CMPX.
Notes
top- No funding round sourced.
Pages like this
not linked directly; found by shared links- CompanyOnc.AI
Shares PD-L1, PD-1, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- PersonBrian I. Rini
Shares Anti-angiogenic therapy, VEGF / VEGFR, PD-1, Immune checkpoint inhibitors.
- PersonTasuku Honjo
Shares PD-L1, PD-1, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares PD-L1, PD-1, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- CompanyXilio Therapeutics
Shares Bispecific antibodies, PD-1, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- PersonGordon J. Freeman
Shares PD-L1, PD-1, Immune checkpoint inhibitors.
- CompanyOncoHost
Shares PD-L1, PD-1, Non-small-cell lung cancer.
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares PD-L1, PD-1, Immune checkpoint inhibitors, Non-small-cell lung cancer.